| (Values in U.S. Thousands) | Mar, 2023 | Mar, 2022 | Mar, 2021 | Mar, 2020 | Mar, 2019 |
| Sales | 80 | 500 | 0 | 0 | 0 |
| Sales Growth | -84.00% | unch | unch | unch | unch |
| Net Income | -14,140 | -13,890 | -6,260 | -4,160 | -4,450 |
| Net Income Growth | -1.80% | -121.89% | -50.48% | +6.52% | -144.51% |
Nemaura Medical Inc
(NMRD)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Nemaura Medical Inc. is a medical technology company. It engages in developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R), BEAT(TM) diabetes, and proBEAT(TM). SugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor. Nemaura Medical Inc. is based in New York, United States.
Fiscal Year End Date: 03/31